288 related articles for article (PubMed ID: 27090585)
21. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds.
Rulyak SJ; Kimmey MB; Veenstra DL; Brentnall TA
Gastrointest Endosc; 2003 Jan; 57(1):23-9. PubMed ID: 12518126
[TBL] [Abstract][Full Text] [Related]
22. Long-term benefit and cost-effectiveness analysis of screening for abdominal aortic aneurysms from a randomized controlled trial.
Lindholt JS; Sørensen J; Søgaard R; Henneberg EW
Br J Surg; 2010 Jun; 97(6):826-34. PubMed ID: 20473995
[TBL] [Abstract][Full Text] [Related]
23. Early detection of pancreatic cancer: why, who, and how to screen.
Klapman J; Malafa MP
Cancer Control; 2008 Oct; 15(4):280-7. PubMed ID: 18813195
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of Abdominal Ultrasound Versus Magnetic Resonance Imaging for Pancreatic Cancer Screening in Familial High-Risk Individuals in Japan.
Kowada A
Pancreas; 2020 Sep; 49(8):1052-1056. PubMed ID: 32769852
[TBL] [Abstract][Full Text] [Related]
25. Assessment of "gene-environment" interaction in cases of familial and sporadic pancreatic cancer.
Yeo TP; Hruban RH; Brody J; Brune K; Fitzgerald S; Yeo CJ
J Gastrointest Surg; 2009 Aug; 13(8):1487-94. PubMed ID: 19459017
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines.
Hayashino Y; Shimbo T; Tsujii S; Ishii H; Kondo H; Nakamura T; Nagata-Kobayashi S; Fukui T
Int J Cardiol; 2007 May; 118(1):88-96. PubMed ID: 16949690
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.
Obradovic M; Mrhar A; Kos M
Eur J Public Health; 2010 Aug; 20(4):415-21. PubMed ID: 20624834
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations.
Peters MLB; Eckel A; Seguin CL; Davidi B; Howard DH; Knudsen AB; Pandharipande PV
JCO Oncol Pract; 2024 Feb; 20(2):278-290. PubMed ID: 38086003
[TBL] [Abstract][Full Text] [Related]
29. Variation in precursor lesions of pancreatic cancer among high-risk groups.
Potjer TP; Schot I; Langer P; Heverhagen JT; Wasser MN; Slater EP; Klöppel G; Morreau HM; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bargello M; Gress TM; Vasen HF; Bartsch DK; ;
Clin Cancer Res; 2013 Jan; 19(2):442-9. PubMed ID: 23172884
[TBL] [Abstract][Full Text] [Related]
30. The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study.
Tamura H; Goto R; Akune Y; Hiratsuka Y; Hiragi S; Yamada M
PLoS One; 2015; 10(7):e0133628. PubMed ID: 26214804
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of Corticosteroid Nasal Spray vs Surgical Therapy in Patients With Severe to Extreme Anatomical Nasal Obstruction.
Teti VP; Akdagli S; Most SP
JAMA Facial Plast Surg; 2016 May; 18(3):165-70. PubMed ID: 26747790
[TBL] [Abstract][Full Text] [Related]
33. Atypical familial presentation of FAMMM syndrome with a high incidence of pancreatic cancer: case finding of asymptomatic individuals by EUS surveillance.
Kluijt I; Cats A; Fockens P; Nio Y; Gouma DJ; Bruno MJ
J Clin Gastroenterol; 2009 Oct; 43(9):853-7. PubMed ID: 19417680
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of universal and risk-based screening for autoimmune thyroid disease in pregnant women.
Dosiou C; Barnes J; Schwartz A; Negro R; Crapo L; Stagnaro-Green A
J Clin Endocrinol Metab; 2012 May; 97(5):1536-46. PubMed ID: 22399510
[TBL] [Abstract][Full Text] [Related]
35. Cohort profile and heritability assessment of familial pancreatic cancer: a nation-wide study.
Tan M; Brusgaard K; Gerdes AM; Mortensen MB; Detlefsen S; Schaffalitzky de Muckadell OB; Joergensen MT
Scand J Gastroenterol; 2021 Aug; 56(8):965-971. PubMed ID: 34165379
[TBL] [Abstract][Full Text] [Related]
36. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer.
Langer P; Kann PH; Fendrich V; Habbe N; Schneider M; Sina M; Slater EP; Heverhagen JT; Gress TM; Rothmund M; Bartsch DK
Gut; 2009 Oct; 58(10):1410-8. PubMed ID: 19470496
[TBL] [Abstract][Full Text] [Related]
37. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.
Poley JW; Kluijt I; Gouma DJ; Harinck F; Wagner A; Aalfs C; van Eijck CH; Cats A; Kuipers EJ; Nio Y; Fockens P; Bruno MJ
Am J Gastroenterol; 2009 Sep; 104(9):2175-81. PubMed ID: 19491823
[TBL] [Abstract][Full Text] [Related]
38. Familial pancreatic cancer--status quo.
Fendrich V; Langer P; Bartsch DK
Int J Colorectal Dis; 2014 Feb; 29(2):139-45. PubMed ID: 23948969
[TBL] [Abstract][Full Text] [Related]
39. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
